These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 23403882)

  • 61. [Physical Therapy for Metabolic Syndrome Prevention in Workers: Novel Role of Physical Therapist].
    Satoh T; Nemoto Y; Utumi T; Munakata M
    Nihon Eiseigaku Zasshi; 2016; 71(2):119-25. PubMed ID: 27246150
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Does microRNA Perturbation Control the Mechanisms Linking Obesity and Diabetes? Implications for Cardiovascular Risk.
    La Sala L; Crestani M; Garavelli S; de Candia P; Pontiroli AE
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33375647
    [TBL] [Abstract][Full Text] [Related]  

  • 63. New targets to treat obesity and the metabolic syndrome.
    Martin KA; Mani MV; Mani A
    Eur J Pharmacol; 2015 Sep; 763(Pt A):64-74. PubMed ID: 26001373
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Obesity and cardiovascular disease risk: research update.
    Melanson KJ; McInnis KJ; Rippe JM; Blackburn G; Wilson PF
    Cardiol Rev; 2001; 9(4):202-7. PubMed ID: 11405900
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Relevance of microRNA in metabolic diseases.
    Price NL; Ramírez CM; Fernández-Hernando C
    Crit Rev Clin Lab Sci; 2014 Dec; 51(6):305-20. PubMed ID: 25034902
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The C1q/TNF-related proteins (CTRPs) in pathogenesis of obesity-related metabolic disorders: Focus on type 2 diabetes and cardiovascular diseases.
    Shanaki M; Shabani P; Goudarzi A; Omidifar A; Bashash D; Emamgholipour S
    Life Sci; 2020 Sep; 256():117913. PubMed ID: 32526287
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Alterations of a Cellular Cholesterol Metabolism Network Are a Molecular Feature of Obesity-Related Type 2 Diabetes and Cardiovascular Disease.
    Ding J; Reynolds LM; Zeller T; Müller C; Lohman K; Nicklas BJ; Kritchevsky SB; Huang Z; de la Fuente A; Soranzo N; Settlage RE; Chuang CC; Howard T; Xu N; Goodarzi MO; Chen YD; Rotter JI; Siscovick DS; Parks JS; Murphy S; Jacobs DR; Post W; Tracy RP; Wild PS; Blankenberg S; Hoeschele I; Herrington D; McCall CE; Liu Y
    Diabetes; 2015 Oct; 64(10):3464-74. PubMed ID: 26153245
    [TBL] [Abstract][Full Text] [Related]  

  • 68. T-cell activation and cardiovascular risk in adults with type 2 diabetes mellitus: A systematic review and meta-analysis.
    Nyambuya TM; Dludla PV; Mxinwa V; Nkambule BB
    Clin Immunol; 2020 Jan; 210():108313. PubMed ID: 31765833
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Gender Differences and Cardiometabolic Risk: The Importance of the Risk Factors.
    Meloni A; Cadeddu C; Cugusi L; Donataccio MP; Deidda M; Sciomer S; Gallina S; Vassalle C; Moscucci F; Mercuro G; Maffei S
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675097
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Global differences in causes and diagnostics of cardio-metabolic diseases].
    Christensen DL; Bygbjerg IC; Meyrowitsch DW
    Ugeskr Laeger; 2017 May; 179(20):. PubMed ID: 28504630
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Extracellular Vesicles: A Novel Target for Exercise-Mediated Reductions in Type 2 Diabetes and Cardiovascular Disease Risk.
    Eichner NZM; Erdbrügger U; Malin SK
    J Diabetes Res; 2018; 2018():7807245. PubMed ID: 30018986
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Metabolic syndrome and risk for Type 2 diabetes.
    Meigs JB
    Expert Rev Endocrinol Metab; 2006 Jan; 1(1):57-66. PubMed ID: 30743769
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Metabolic syndrome, obesity and urolithiasis].
    Traxer O; Safar H; Daudon M; Haymann JP
    Prog Urol; 2006 Sep; 16(4):418-20. PubMed ID: 17069032
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Neglected cardiovascular risk factors.
    Lüscher TF
    Eur Heart J; 2015 Oct; 36(39):2621-3. PubMed ID: 26468255
    [No Abstract]   [Full Text] [Related]  

  • 75. The "Common Soil Hypothesis" Revisited-Risk Factors for Type 2 Diabetes and Cardiovascular Disease.
    Fernandes Silva L; Vangipurapu J; Laakso M
    Metabolites; 2021 Oct; 11(10):. PubMed ID: 34677406
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Transcription Factor KLF14 and Metabolic Syndrome.
    Yang Q; Civelek M
    Front Cardiovasc Med; 2020; 7():91. PubMed ID: 32548128
    [TBL] [Abstract][Full Text] [Related]  

  • 77. L-carnitine: implications in the treatment of the metabolic syndrome and Type 2 diabetes.
    Anuradha CV
    Expert Rev Endocrinol Metab; 2008 Nov; 3(6):777-783. PubMed ID: 30764066
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Postprandial Endotoxemia: A Significant Contributor to Chronic Diseases.
    Campbell AW
    Altern Ther Health Med; 2017 May; 23(2):8-10. PubMed ID: 28646635
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Challenges in developing drugs for the metabolic syndrome.
    Matfin G
    Curr Diab Rep; 2008 Feb; 8(1):31-6. PubMed ID: 18366996
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Introduction: the metabolic cardiovascular syndrome.
    Arnesen H
    J Cardiovasc Pharmacol; 1992; 20 Suppl 8():S1-4. PubMed ID: 1283761
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.